Phase

OSE Immunotherapeutics Declares Presentation of TEDOVA Part 2 Topline Outcomes of Tedopi® in Ovarian Most cancers on the ASCO 2026 Assembly
Press Releases

OSE Immunotherapeutics Declares Presentation of TEDOVA Part 2 Topline Outcomes of Tedopi® in Ovarian Most cancers on the ASCO 2026 Assembly

GEX Administration Publicizes Strategic Growth Plan for Subsequent Part of Development
Press Releases

GEX Administration Publicizes Strategic Growth Plan for Subsequent Part of Development

Smithfield Meals Publicizes Built-in Company Group to Drive Subsequent Section of Progress
Partnerships

Smithfield Meals Publicizes Built-in Company Group to Drive Subsequent Section of Progress

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Section 2/3 Scientific Trial of SIL204 in Domestically Superior Pancreatic Most cancers
Stock Market

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Section 2/3 Scientific Trial of SIL204 in Domestically Superior Pancreatic Most cancers

Nasus Pharma Advances NS002 In direction of Pivotal Examine Following Optimistic Part 2; Studies Annual Outcomes and Offers Enterprise Replace
Stock Market

Nasus Pharma Advances NS002 In direction of Pivotal Examine Following Optimistic Part 2; Studies Annual Outcomes and Offers Enterprise Replace

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Part 2/3 Scientific Trial of SIL204 in Regionally Superior Pancreatic Most cancers
Stock Market

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Part 2/3 Scientific Trial of SIL204 in Regionally Superior Pancreatic Most cancers

Bitcoin Everlight Opens Section 2 Presale as Shard Activations Proceed Throughout All Three Tiers
Product / Services

Bitcoin Everlight Opens Section 2 Presale as Shard Activations Proceed Throughout All Three Tiers